For how long should we use symptomatic therapies to treat people with Alzheimer disease?

TY - JOUR

T1 - For how long should we use symptomatic therapies to treat people with Alzheimer disease?

AU - Rockwood, Kenneth

PY - 2014/12/1

Y1 - 2014/12/1

KW - Alzheimer disease

KW - Cholinesterase inhibitor

KW - Clinical trial

KW - Dementia

KW - Donepezil

KW - Galantamine

KW - Rivastigmine

KW - Symptoms

UR - http://www.scopus.com/inward/record.url?scp=84919434237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919434237&partnerID=8YFLogxK

U2 - 10.1177/070674371405901201

DO - 10.1177/070674371405901201

M3 - Editorial

C2 - 25702359

AN - SCOPUS:84919434237

SN - 0706-7437

VL - 59

SP - 615

EP - 617

JO - Canadian Journal of Psychiatry

JF - Canadian Journal of Psychiatry

IS - 12

ER -